Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Precision oncology: the intention-to-treat analysis fallacy

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.002Source: DataRank Database

Precision oncology: the intention-to-treat analysis fallacy is a research paper published in European Journal of Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)Impact (FWCI 0.42)OA: hybridTopics (55)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Shumei Kato ORCID,Ryosuke Okamura ORCID,Razelle Kurzrock ORCID,Jason K. Sicklick ORCID

Live enrichment

PubMed:32422506 PMC:PMC7786388 OpenAlex:https://openalex.org/W3025822327

NIH

Grant: P30CA023100

NIH

Grant: K08CA168999

NIH

Grant: R21CA192072

NIH

Grant: R01CA226803

FDA HHS

Grant: R01 FD006334

National Institutes of Health

Grant: 5R21CA192072-02

Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor Syndrome

National Institutes of Health

Grant: 1R01CA226803-01A1

Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal Tumor

National Institutes of Health

Grant: 5K08CA168999-03

Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST

National Institutes of Health

Grant: 3P30CA023100-25S4

Specialized Cancer Center Support Grant

Blueprint Medicines

Sequenom

Guardant Health

Incyte

Konica Minolta

Novartis Pharmaceuticals

Omniseq

Joan and Irwin Jacobs Philanthropic Fund

Merck Serono

Pfizer

Amgen

David Foundation

Foundation Medicine Inc.

Grifols

Genentech

Jon Schneider Memorial Cancer Research Fund

Kristen Ann Carr Fund

FWCI

0.42

Citation Percentile

0.5%

Citation Trend

2020

2021

2023

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ejca.2020.04.002

HYBRIDhttps://doi.org/10.1016/j.ejca.2020.04.002

publisherhttps://doi.org/10.1016/j.ejca.2020.04.002

publisherhttps://api.elsevier.com/content/article/PII:S095980492030191X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S095980492030191X?httpAccept=text/plain

Fields of Study

Cancer Genomics and DiagnosticsStatistical Methods in Clinical TrialsLung Cancer Treatments and MutationsMedicine03 medical and health sciences0302 clinical medicine

MeSH Terms

False Positive ReactionsHumansMedical OncologyNeoplasmsResearch DesignBiasRandomized Controlled Trials as TopicTreatment OutcomeProtein Kinase InhibitorsIntention to Treat AnalysisPrecision MedicineMolecular Targeted Therapy

Keywords

MedicineRandomized controlled trialPrecision medicineClinical trialConfoundingOncologyInternal medicinePopulationBiomarkerPathologyIntention-to-treatPrecision OncologyOncology and CarcinogenesisClinical Trials and Supportive Activities610Medical OncologyCancer GenomicsBiasClinical ResearchNeoplasmsGeneticsHumansFalse Positive ReactionsOncology & CarcinogenesisMolecular Targeted TherapyProtein Kinase InhibitorsCancerRandomized Controlled Trials as TopicBiomedical and Clinical SciencesHuman GenomeIntention to Treat AnalysisGood Health and Well BeingTreatment Outcome5.1 PharmaceuticalsResearch Design6.1 PharmaceuticalsPublic Health and Health Services

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being